Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Vernalis plc    VER   GB00B3Y5L754

Delayed Quote. Delayed  - 12/02 05:34:59 pm
34.25 GBp   +1.86%
12/01 VERNALIS PLC : AGM Statement
12/01 VERNALIS : Takes Steps To Drive Demand For Tuzistra, Progress Pipeli..
10/24 VERNALIS : Notice of Annual Report and AGM
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
11/28/2016 11/29/2016 11/30/2016 12/01/2016 12/02/2016 Date
32.875(c) 33.25(c) 33.25(c) 33.625(c) 34.25(c) Last
73 424 50 736 51 302 176 735 53 411 Volume
-1.50% +1.14% 0.00% +1.13% +1.86% Change
More quotes
Financials ( GBP)
Sales 2017 13,1 M
EBIT 2017 -37,8 M
Net income 2017 -32,2 M
Finance 2017 8,80 M
Yield 2017 -
Sales 2018 39,1 M
EBIT 2018 -19,5 M
Net income 2018 -6,31 M
Finance 2018 3,67 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 13,1x
EV / Sales2018 4,52x
Capitalization 180 M
More Financials
Company
Vernalis Plc engages in the research, development, and commercialization of pharmaceutical products under the Tuzistra XR brand.The company was founded by Keith G. McCullagh in 1986 and is headquartered in Winnersh, United Kingdom. 
More about the company
Surperformance© ratings of Vernalis plc
Trading Rating : Investor Rating :
More Ratings
Latest news on VERNALIS PLC
12/01 VERNALIS PLC : AGM Statement
12/01 VERNALIS : Takes Steps To Drive Demand For Tuzistra, Progress Pipeline
10/24 VERNALIS : Notice of Annual Report and AGM
10/20 VERNALIS : Begins Promotion Of MOXATAG® Amoxicillin Extended-Release Tablets To ..
10/11 VERNALIS : *panmure cuts vernalis plc price target to 65 (76) pence - 'buy'
09/29 VERNALIS : Makes "Significant Progress" In Year On Tuzistra's US Launch
09/29 VERNALIS : Results Announcement for the 12 months ended 30 June 2016
09/29 VERNALIS PLC : Announces Results Announcement for the 12 Months Ended 30 June 20..
09/26VERNALIS PLC : annual earnings release
09/13 VERNALIS : Notice of Full Year Results
More news
Sector news : Biotechnology & Medical Research - NEC
01:25aDJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
09/29 Vernalis reports FY16 results
03/17 Vernalis ADR reports 6M'15 results
2015 Vernalis acquires U.S. rights to extended-release antibiotic
Advertisement
Chart VERNALIS PLC
Duration : Period :
Vernalis plc Technical Analysis Chart | VER | GB00B3Y5L754 | 4-Traders
Full-screen chart
Technical analysis trends VERNALIS PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 0,79  GBP
Spread / Average Target 131%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Ian Garland Chief Executive Officer & Executive Director
Peter John Fellner Non-Executive Chairman
David MacKney Chief Financial Officer & Executive Director
Pascal Borderies Senior Vice President-Medical Affairs
Carol C. Ferguson Senior Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
VERNALIS PLC-52.56%229
INCYTE CORPORATION-5.68%19 219
QUINTILES IMS HOLDINGS..11.90%18 225
CELLTRION, INC.--.--%9 953
SEATTLE GENETICS, INC.44.41%9 442
LONZA GROUP AG11.34%9 247
More Results